Basis: (FMP quote price / unrounded diluted TTM EPS) / explicitly dated EPS growth percent. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-09-11T10:20:29.679Z.
Calculation as of: 2026-09-11T10:20:29.679Z.
Quote observation: 2026-09-10T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 528d3ba9148e81a59322c16104731b7399dfc1101138210616e0d0efbf11ec7a
PEG RATIO
N/A
AstraZeneca PLC
Market Cap
$247.58B
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| AstraZeneca PLC (AZN) | $247.58B | N/A |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.15B | N/A |
| Amgen Inc. (AMGN)vs › | $206.42B | N/A |
| Novo Nordisk A/S (NVO)vs › | $195.43B | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $179.79B | N/A |
| Abbott Laboratories (ABT)vs › | $178.87B | N/A |
| Pfizer Inc. (PFE)vs › | $157.59B | N/A |
| Roche Holding AG (RHHBY)vs › | $339.06B | N/A |
| UnitedHealth Group Incorporated (UNH)vs › | $352.61B | N/A |
| Danaher Corporation (DHR)vs › | $141.00B | N/A |
PEG Ratio
N/A
P/E Ratio
24.0
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
